In this interview Alex Hawes (LGC; Cambridge, UK) discusses the topic of immunogenicity. She explains how she developed her first anti-drug antibody analytical method and the platforms LGC use in their immunogenicity sector.
Dr Bonner serves as a scientific resource and technical advisor for both clients and internal…
Immunogenicity is the patient’s ability to generate antibodies, specific to the ‘dosed protein therapeutic’. In this blog post, Franklin Spriggs (KCAS; KS, USA) explains the importance of antibody-drug antibody assays and how data can be used towards safety profiles.
In this interview, Joao discusses the molecules and products he reviews and how important it is to understand how they affect efficacy and safety in patients.
To kick-start this our special focus on immunogencity, we wanted to hear your thoughts on the topic. Complete our short survey on immunogencity and be the first to receive our informative infographic collated from the survey results.
Poster: novel approach to immunogenicity testing for therapeutics with high prevalence of pre-existing antibodies
Developing Immunogenicity methods for patient populations with a high prevalence of pre-existing antibodies pose challenges that are difficult to validate. Care must be taken to acknowledge these risks during development of screening strategy and method development. In this case study, the therapeutic consisted of two domains (X-Y) in which domain X has homology to a childhood vaccine with known immunogenicity in ≥90% of the U.S. population. Screening strategy includes domain specificity testing using inhibition by excess of each domain for confirmatory cut point determination.
Considerations for developing and validating an LC–MS biomarker assay using the surrogate peptide approach
In this editorial, Timothy Sikorski (GSK; PA, USA), discusses particular considerations for developing and validating LC–MS biomarker assays using the surrogate peptide approach.
BioAgilytix (NC, USA) have announced their partnership with Sword Bio (IL, USA), to expand their bioanalytical services to include Sword Bio’s detection platform for immunoassays.
In this conference report we discuss our highlights from the 12th Workshop on Recent Issues in Bioanalysis – Where Regulators and Industry Convene (WRIB; Philadelphia, USA; 9–13 April).
Read time: 5:30 mins
In this interview, Arno Kromminga discusses the benefits and challenges associated with current methods, and what he believes the future holds for immunogencity.